Structural Dynamics of the SARS-CoV-2 Spike Protein: A 2-Year Retrospective Analysis of SARS-CoV-2 Variants (from Alpha to Omicron) Reveals an Early Divergence between Conserved and Variable Epitopes

We analyzed the epitope evolution of the spike protein in 1,860,489 SARS-CoV-2 genomes. The structural dynamics of these epitopes was determined by molecular modeling approaches. The D614G mutation, selected in the first months of the pandemic, is still present in currently circulating SARS-CoV-2 strains. This mutation facilitates the conformational change leading to the demasking of the ACE2 binding domain. D614G also abrogated the binding of facilitating antibodies to a linear epitope common to SARS-CoV-1 and SARS-CoV-2. The main neutralizing epitope of the N-terminal domain (NTD) of the spike protein showed extensive structural variability in SARS-CoV-2 variants, especially Delta and Omicron. This epitope is located on the flat surface of the NTD, a large electropositive area which binds to electronegatively charged lipid rafts of host cells. A facilitating epitope located on the lower part of the NTD appeared to be highly conserved among most SARS-CoV-2 variants, which may represent a risk of antibody-dependent enhancement (ADE). Overall, this retrospective analysis revealed an early divergence between conserved (facilitating) and variable (neutralizing) epitopes of the spike protein. These data aid in the designing of new antiviral strategies that could help to control COVID-19 infection by mimicking neutralizing antibodies or by blocking facilitating antibodies.

[1]  Maolin Lu,et al.  Structural Plasticity and Immune Evasion of SARS-CoV-2 Spike Variants , 2022, Viruses.

[2]  An Wang,et al.  Antibody-dependent enhancement (ADE) of SARS-CoV-2 pseudoviral infection requires FcγRIIB and virus-antibody complex with bivalent interaction , 2022, Communications Biology.

[3]  A. Takada,et al.  Multiple Routes of Antibody-Dependent Enhancement of SARS-CoV-2 Infection , 2022, Microbiology spectrum.

[4]  J. Kamil,et al.  Structural Dynamics and Molecular Evolution of the SARS-CoV-2 Spike Protein , 2022, mBio.

[5]  S. K. Janaka,et al.  Anti-SARS-CoV-2 IgG and IgA antibodies in COVID-19 convalescent plasma do not enhance viral infection , 2022, PloS one.

[6]  P. Fournier,et al.  Culture and identification of a “Deltamicron” SARS‐CoV‐2 in a three cases cluster in southern France , 2022, medRxiv.

[7]  S. Karmakar,et al.  Neutralizing Antibodies and Antibody-Dependent Enhancement in COVID-19: A Perspective , 2022, Journal of the Indian Institute of Science.

[8]  P. Fournier,et al.  Limited spread of a rare spike E484K-harboring SARS-CoV-2 in Marseille, France , 2022, Archives of Virology.

[9]  P. Fournier,et al.  Characteristics of the first 1119 SARS‐CoV‐2 Omicron variant cases, in Marseille, France, November−December 2021 , 2022, Journal of medical virology.

[10]  B. La Scola,et al.  The puzzling mutational landscape of the SARS‐2‐variant Omicron , 2022, Journal of medical virology.

[11]  A. Shukla,et al.  Antibody-dependent enhancement of virus infection and disease: implications in COVID-19 , 2022, Journal of basic and clinical physiology and pharmacology.

[12]  P. Colson,et al.  The emergence, dynamics and significance of SARS-CoV-2 variants , 2022, New Microbes and New Infections.

[13]  P. Zhou,et al.  Antibody-Dependent Enhancement of SARS-CoV-2 Infection of Human Immune Cells: In Vitro Assessment Provides Insight in COVID-19 Pathogenesis , 2021, Viruses.

[14]  T. Shioda,et al.  The potential of COVID-19 patients’ sera to cause antibody-dependent enhancement of infection and IL-6 production , 2021, Scientific Reports.

[15]  Zhancheng Gao,et al.  Detection of Antibodies Against the SARS-CoV-2 Spike Protein and Analysis of the Peripheral Blood Mononuclear Cell Transcriptomic Profile, 15 Years After Recovery From SARS , 2021, Frontiers in Cellular and Infection Microbiology.

[16]  D. Wesemann,et al.  Membrane fusion and immune evasion by the spike protein of SARS-CoV-2 Delta variant , 2021, Science.

[17]  S. Subramanian,et al.  Increases in COVID-19 are unrelated to levels of vaccination across 68 countries and 2947 counties in the United States , 2021, European Journal of Epidemiology.

[18]  D. Barh,et al.  Periodically aperiodic pattern of SARS-CoV-2 mutations underpins the uncertainty of its origin and evolution , 2021, Environmental Research.

[19]  Yang Li,et al.  Antibody dependent enhancement: Unavoidable problems in vaccine development , 2021, Advances in Immunology.

[20]  L. Du,et al.  Neutralizing antibodies for the prevention and treatment of COVID-19 , 2021, Cellular & Molecular Immunology.

[21]  A. Iwasaki,et al.  COVID-19 vaccines: Keeping pace with SARS-CoV-2 variants , 2021, Cell.

[22]  G. R. Schleder,et al.  Structural dynamics of SARS-CoV-2 nucleocapsid protein induced by RNA binding , 2021, bioRxiv.

[23]  S. Madhi,et al.  Emergence and phenotypic characterization of C.1.2, a globally detected lineage that rapidly accumulated mutations of concern , 2021 .

[24]  D. Standley,et al.  The SARS-CoV-2 Delta variant is poised to acquire complete resistance to wild-type spike vaccines , 2021, bioRxiv.

[25]  R. Ruprecht,et al.  Mucosal AIDS virus transmission is enhanced by antiviral IgG isolated early in infection , 2021, AIDS.

[26]  Y. Liu,et al.  The reproductive number of the Delta variant of SARS-CoV-2 is far higher compared to the ancestral SARS-CoV-2 virus , 2021, Journal of travel medicine.

[27]  J. Fantini,et al.  Longitudinal study of a SARS-CoV-2 infection in an immunocompromised patient with X-linked agammaglobulinemia , 2021, Journal of Infection.

[28]  D. Barh,et al.  Emergence of unique SARS-CoV-2 ORF10 variants and their impact on protein structure and function , 2021, International Journal of Biological Macromolecules.

[29]  X. Xia Detailed Dissection and Critical Evaluation of the Pfizer/BioNTech and Moderna mRNA Vaccines , 2021, Vaccines.

[30]  C. Woods,et al.  In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies , 2021, Cell.

[31]  W. Niu,et al.  ACE2 can act as the secondary receptor in the FcγR-dependent ADE of SARS-CoV-2 infection , 2021, iScience.

[32]  J. Fantini,et al.  Structural dynamics of SARS-CoV-2 variants: A health monitoring strategy for anticipating Covid-19 outbreaks , 2021, Journal of Infection.

[33]  J. Nielsen,et al.  Vaccine effectiveness of the BNT162b2 mRNA COVID-19 vaccine against RT-PCR confirmed SARS-CoV-2 infections, hospitalisations and mortality in prioritised risk groups , 2021, medRxiv.

[34]  William T. Harvey,et al.  Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7 , 2021, Cell Reports.

[35]  D. Standley,et al.  An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies , 2021, Cell.

[36]  D. Barh,et al.  Implications derived from S-protein variants of SARS-CoV-2 from six continents , 2021, bioRxiv.

[37]  H. Schuitemaker,et al.  Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease , 2021, NPJ vaccines.

[38]  V. Gordeliy,et al.  Structure and dynamics of the SARS-CoV-2 envelope protein monomer , 2021, bioRxiv.

[39]  S. Rowland-Jones,et al.  The D614G mutations in the SARS-CoV-2 spike protein: Implications for viral infectivity, disease severity and vaccine design , 2020, Biochemical and Biophysical Research Communications.

[40]  R. Shukla,et al.  Antibody-Dependent Enhancement: A Challenge for Developing a Safe Dengue Vaccine , 2020, Frontiers in Cellular and Infection Microbiology.

[41]  J. Fantini,et al.  Leveraging coronavirus binding to gangliosides for innovative vaccine and therapeutic strategies against COVID-19 , 2020, Biochemical and Biophysical Research Communications.

[42]  S. Tripathi,et al.  Intrinsic ADE: The Dark Side of Antibody Dependent Enhancement During Dengue Infection , 2020, Frontiers in Cellular and Infection Microbiology.

[43]  Peter B Rosenthal,et al.  Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion , 2020, Nature.

[44]  Yifan Cheng,et al.  Antibody-dependent enhancement of coronavirus , 2020, International Journal of Infectious Diseases.

[45]  S. Rowland-Jones,et al.  Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus , 2020, Cell.

[46]  Qiang Zhou,et al.  A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2 , 2020, Science.

[47]  Eric J Yager Antibody-dependent enhancement and COVID-19: Moving toward acquittal , 2020, Clinical Immunology.

[48]  J. Fantini,et al.  Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal , 2020, International Journal of Antimicrobial Agents.

[49]  A. Iwasaki,et al.  The potential danger of suboptimal antibody responses in COVID-19 , 2020, Nature Reviews Immunology.

[50]  E. Ooi,et al.  Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development , 2020, EBioMedicine.

[51]  Jacques Fantini,et al.  Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection , 2020, International Journal of Antimicrobial Agents.

[52]  Shibo Jiang,et al.  Don’t rush to deploy COVID-19 vaccines and drugs without sufficient safety guarantees , 2020, Nature.

[53]  Jason A. Tetro,et al.  Is COVID-19 receiving ADE from other coronaviruses? , 2020, Microbes and Infection.

[54]  B. Graham,et al.  Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation , 2020, Science.

[55]  Fang Li,et al.  Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry , 2019, Journal of Virology.

[56]  R. Kulkarni Antibody-Dependent Enhancement of Viral Infections , 2019, Dynamics of Immune Activation in Viral Diseases.

[57]  H. Turner,et al.  Antibody-dependent enhancement of influenza disease promoted by increase in hemagglutinin stem flexibility and virus fusion kinetics , 2019, Proceedings of the National Academy of Sciences.

[58]  T. Takano,et al.  Pathogenesis of oral type I feline infectious peritonitis virus (FIPV) infection: Antibody-dependent enhancement infection of cats with type I FIPV via the oral route , 2019, The Journal of veterinary medical science.

[59]  S. Varga,et al.  The CD8 T Cell Response to Respiratory Virus Infections , 2018, Front. Immunol..

[60]  A. García-Sastre,et al.  Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity , 2017, Science.

[61]  J. Taubenberger,et al.  IgG antibodies to dengue enhanced for FcγRIIIA binding determine disease severity , 2017, Science.

[62]  G. Screaton,et al.  Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus , 2016, Nature Immunology.

[63]  Krishna Shankara Narayanan,et al.  Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus , 2016, Human vaccines & immunotherapeutics.

[64]  Jing Xie,et al.  Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on Infection in Non-human Primates , 2016, ACS infectious diseases.

[65]  T. Takano,et al.  Mutation of neutralizing/antibody-dependent enhancing epitope on spike protein and 7b gene of feline infectious peritonitis virus: Influences of viral replication in monocytes/macrophages and virulence in cats , 2011, Virus Research.

[66]  Torsten Schwede,et al.  Automated comparative protein structure modeling with SWISS‐MODEL and Swiss‐PdbViewer: A historical perspective , 2009, Electrophoresis.

[67]  T. Takano,et al.  Antibody-dependent enhancement occurs upon re-infection with the identical serotype virus in feline infectious peritonitis virus infection. , 2008, The Journal of veterinary medical science.

[68]  Taehoon Kim,et al.  CHARMM‐GUI: A web‐based graphical user interface for CHARMM , 2008, J. Comput. Chem..

[69]  René Thomsen,et al.  MolDock: a new technique for high-accuracy molecular docking. , 2006, Journal of medicinal chemistry.

[70]  Kwanyee Leung,et al.  Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[71]  H. Pearson Caution raised over SARS vaccine , 2005, Nature.

[72]  Y. Kawaoka,et al.  Antibody-Dependent Enhancement of Ebola Virus Infection , 2003, Journal of Virology.

[73]  Shinji Watanabe,et al.  Infectivity-Enhancing Antibodies to Ebola Virus Glycoprotein , 2001, Journal of Virology.

[74]  D. Morens,et al.  Antibody-dependent enhancement of infection and the pathogenesis of viral disease. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[75]  M. Froimowitz,et al.  HyperChem: a software package for computational chemistry and molecular modeling. , 1993, BioTechniques.

[76]  H. Vennema,et al.  Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization , 1990, Journal of virology.

[77]  S. Halstead,et al.  Studies on the pathogenesis of dengue infection in monkeys. II. Clinical laboratory responses to heterologous infection. , 1973, The Journal of infectious diseases.

[78]  S. Halstead,et al.  Hemorrhagic fever in Thailand; recent knowledge regarding etiology. , 1967, Japanese journal of medical science & biology.

[79]  J. Orient Negative Evidence : Antibody-Dependent Enhancement , 2022 .

[80]  H. Arase,et al.  [Infectivity-enhancing antibodies against SARS-CoV-2]. , 2021, Uirusu.

[81]  P. V. Bramhachari Dynamics of Immune Activation in Viral Diseases , 2020 .

[82]  J. Fantini,et al.  Hybrid In Silico/In Vitro Approaches for the Identification of Functional Cholesterol-Binding Domains in Membrane Proteins. , 2017, Methods in molecular biology.

[83]  K. Yoon,et al.  Antibody-dependent enhancement of virus infection and disease. , 2003, Viral immunology.